174 related articles for article (PubMed ID: 30918304)
1. Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers.
Bischof K; Knappskog S; Hjelle SM; Stefansson I; Woie K; Salvesen HB; Gjertsen BT; Bjorge L
Sci Rep; 2019 Mar; 9(1):5244. PubMed ID: 30918304
[TBL] [Abstract][Full Text] [Related]
2. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.
Bischof K; Knappskog S; Stefansson I; McCormack EM; Trovik J; Werner HMJ; Woie K; Gjertsen BT; Bjorge L
BMC Cancer; 2018 Jun; 18(1):684. PubMed ID: 29940909
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
Tuna M; Ju Z; Yoshihara K; Amos CI; Tanyi JL; Mills GB
Br J Cancer; 2020 Feb; 122(3):405-412. PubMed ID: 31780779
[TBL] [Abstract][Full Text] [Related]
4. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
[TBL] [Abstract][Full Text] [Related]
5. The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer.
Hofstetter G; Berger A; Berger R; Zorić A; Braicu EI; Reimer D; Fiegl H; Marth C; Zeimet AG; Ulmer H; Moll U; Zeillinger R; Concin N
Int J Gynecol Cancer; 2012 Mar; 22(3):372-9. PubMed ID: 22246403
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles.
Oh L; Hainaut P; Blanchet S; Ariffin H
BMC Cancer; 2020 Feb; 20(1):110. PubMed ID: 32041553
[TBL] [Abstract][Full Text] [Related]
8. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
9. Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.
Hofstetter G; Berger A; Schuster E; Wolf A; Hager G; Vergote I; Cadron I; Sehouli J; Braicu EI; Mahner S; Speiser P; Marth C; Zeimet AG; Ulmer H; Zeillinger R; Concin N
Br J Cancer; 2011 Nov; 105(10):1593-9. PubMed ID: 22009029
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
[TBL] [Abstract][Full Text] [Related]
11. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
12. p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.
Bourdon JC; Khoury MP; Diot A; Baker L; Fernandes K; Aoubala M; Quinlan P; Purdie CA; Jordan LB; Prats AC; Lane DP; Thompson AM
Breast Cancer Res; 2011 Jan; 13(1):R7. PubMed ID: 21251329
[TBL] [Abstract][Full Text] [Related]
13. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
14. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
[TBL] [Abstract][Full Text] [Related]
15. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53 isoforms in renal cell carcinoma.
Song W; Huo SW; Lü JJ; Liu Z; Fang XL; Jin XB; Yuan MZ
Chin Med J (Engl); 2009 Apr; 122(8):921-6. PubMed ID: 19493415
[TBL] [Abstract][Full Text] [Related]
17. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
[TBL] [Abstract][Full Text] [Related]
18. The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers.
Biatta CM; Paudice M; Greppi M; Parrella V; Parodi A; De Luca G; Cerruti GM; Mammoliti S; Caroti C; Menichini P; Fronza G; Pesce S; Marcenaro E; Vellone VG
Front Immunol; 2023; 14():1221605. PubMed ID: 37680633
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
Kang HJ; Chun SM; Kim KR; Sohn I; Sung CO
PLoS One; 2013; 8(8):e72609. PubMed ID: 23967324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
